Moderna Slows Enrollment In Large COVID-19 Vaccine Trial To Ensure Sufficient Representation Of Minorities
- September 08, 2020
CNBC (9/4, Tirrell, Miller) reported Moderna is slowing enrollment in the large trial of its COVID-19 vaccine slightly “to ensure it has sufficient representation of minorities most at risk for the disease, its chief executive said.” As of August 28, the trial “had enrolled 17,458, 24% of whom are from communities of color.” Moderna CEO Stephane Bancel said, “We believe we could have one of the best vaccines. ... We want to ensure we have data for all the people who could benefit and be protected.”
BioCentury (9/4, Eaton, Subscription Publication) also covered the story.